Zydus Lifesciences Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Zydus Lifesciences ha aumentado sus beneficios a una tasa media anual de 11.4%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 6.7% al año. La rentabilidad financiera de Zydus Lifesciences es de 14.6%, y sus márgenes netos son de 15.5%.

Información clave

11.4%

Tasa de crecimiento de los beneficios

11.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	17.5%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera	14.6%
Margen neto	15.5%
Próxima actualización de resultados	30 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Mar 18

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Aug 09

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 25

Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50

Jul 10

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Jul 07

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 23

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50

Jun 09

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50

May 26

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Zydus Lifesciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NSEI:ZYDUSLIFE Ingresos, gastos y beneficios (INR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	190,241	29,562	40,238
30 Sep 23	187,760	28,109	38,955
30 Jun 23	184,127	25,262	38,143
31 Mar 23	172,374	19,649	37,649
31 Dec 22	164,335	20,785	34,572
30 Sep 22	157,110	19,629	33,594
30 Jun 22	153,361	21,710	33,072
31 Mar 22	151,099	22,416	32,498
31 Dec 21	157,609	23,267	33,869
30 Sep 21	157,389	23,269	34,155
30 Jun 21	156,130	22,600	33,716
31 Mar 21	144,035	22,016	31,250
31 Dec 20	150,076	18,465	33,882
30 Sep 20	148,501	16,932	33,738
30 Jun 20	143,967	13,270	33,550
31 Mar 20	142,531	11,766	33,080
31 Dec 19	142,338	12,448	30,652
30 Sep 19	141,736	13,816	29,702
30 Jun 19	137,682	16,919	28,947
31 Mar 19	131,656	18,488	28,315
31 Dec 18	126,706	19,954	26,962
30 Sep 18	123,526	20,305	26,377
30 Jun 18	126,133	21,168	25,801
31 Mar 18	119,049	17,946	24,874
31 Dec 17	111,691	15,705	23,076
30 Sep 17	102,206	13,511	22,178
30 Jun 17	93,397	12,277	15,718
31 Mar 17	93,765	14,904	20,774
31 Dec 16	97,494	11,323	22,840
30 Sep 16	97,971	12,812	22,110
30 Jun 16	97,221	14,186	13,863
31 Mar 16	94,268	19,339	19,875
31 Dec 15	95,901	14,843	26,749
30 Sep 15	92,453	13,766	26,744
30 Jun 15	89,795	12,638	26,277
31 Mar 15	86,513	11,506	19,060
31 Dec 14	82,955	10,394	24,740
30 Sep 14	79,777	9,435	24,184
30 Jun 14	76,165	8,488	24,041
31 Mar 14	72,034	8,036	23,771
31 Dec 13	68,204	8,266	21,595
30 Sep 13	65,528	7,430	21,306
30 Jun 13	64,007	6,561	9,356

Ingresos de calidad: ZYDUSLIFE tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (15.5%) de ZYDUSLIFE son superiores a los del año pasado (12.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de ZYDUSLIFE han crecido un 11.4% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de ZYDUSLIFE en el último año (42.2%) supera su media de 5 años (11.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ZYDUSLIFE en el último año (42.2%) superó al de la industria Pharmaceuticals 23.8%.

Zydus Lifesciences Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Zydus Group Reportedly Looks to Sell Cliantha Research

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Febuxostat Tablets

Zydus Lifesciences Limited Receives Two Final Approvals from the USFDA for Silodosin Capsules and Pregabalin Capsules

Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration to Market Topiramate Extended-Release Capsules

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) entered into a Business Transfer Agreement to acquire Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma for approximately INR 470 million.

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Famotidine Injection

Zydus Lifesciences Limited Gets Exclusive Marketing Rights for CanAssist Breast

Insufficient new directors

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Acetaminophen Injection

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Micafungin for Injection

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Ketorolac Tromethamine Tablets

Investor sentiment improved over the past week

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Lenalidomide Capsules 5 Mg, 10 Mg, 15 Mg and 25 Mg

Zydus Lifesciences Limited Receives Final Approval and 180 Days Shared Exclusivity from the USFDA for Cariprazine Capsules

Zydus Lifesciences Ltd. Achieves Positive Proof-of-Concept in its Phase 2 Clinical Study of ZYIL1, in Patients with CAPS

Zydus Lifesciences Ltd. Announces Phase IV DREAM-CKD Trial to Generate Real World Evidence of Desidustat in Patients with Chronic Kidney Disease Induced Anemia

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Zydus Receives Final Approval from the USFDA for Ivermectin Cream

Desglose de ingresos y gastos
Beta